We compared, in a double-blind randomised study, intramuscular ketorolac 30 mg (n=49) and intramuscular pethidine 75 mg (n =51) for analgesia after elective caesarean section under general anaesthesia.
Postoperative analgesia is often prescribed using intramuscular (IM) "whenever necessary" (PRN) opioid regimens with poor results and low patient satisfaction. I However, more ideal methods such as epidural analgesia or patient-controlled analgesia may not be available or suitable for every patient. A recent survey found that the majority of anaesthetists thought that the intramuscular PRN regimen was the safest method of administration in a postoperative ward. 2 In such situations, it would be valuable to have available an effective analgesic free of problems associated with the administration of opioids.
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) which provides analgesia comparable with opioid drugs, ketorolac 30 mg being as effective as morphine 12 mg or pethidine 100 mg. lA Ketorolac is free from opioid-related side-effects such as respiratory depression, sedation, nausea and vomItmg and the duration of action is approximately four to six hours. J,4 Ketorolac is not a Controlled Drug so there are less logistic problems with its administration compared with opioid drugs.
We believed that ketorolac could be useful in the post-natal ward and compared ketorolac 30 mg IM and pethidine 75 mg IM for analgesia after elective caesarean section under general anaesthesia.
METHODS
The Clinical Research Ethics Sub-committee approved this single-dose double-blind comparative study and all patients gave written consent. We studied one hundred ASA 1-11 Asian women who requested general anaesthesia for elective caesarean section. All women had uncomplicated term pregnancies and indicated that they would bottle-feed their babies.
Anaesthesia was induced with thiopentone 4-5 mg/kg, suxamethoniun 1.5 mg/kg and maintained with atracurium, nitrous oxide and isoflurane. Fentanyl 100 /lg and oxytocin 10 mg were given after delivery and neuromuscular block was antagonised with neostigmine and atropine at the end of surgery.
On arrival in the recovery room, patients were asked to grade their initial pain severity as mild, moderate, severe or very severe. Only patients with moderate or severe pain and requesting analgesia were entered into the trial. When patients requested analgesia, they marked a baseline 10 cm visual analogue pain scale (VAS) and were allocated to receive either pethidine 75 mg or ketorolac 30 mg according to a randomly generated sequence. The study drug was given by IM injection into the lateral thigh. Analgesia was assessed by an investigator blinded to the study drug. The VAS and a verbal four-point scale (no relief, some relief, marked relief or complete pain relief) were recorded at 0.5, 1, 2, 3, 4, 5, 6 hours or until the patient requested further analgesia. At 6 hours, or at the time of request for further analgesia, whichever was earlier, a final VAS was recorded and overall analgesia (no relief, some relief, marked relief, complete relief) was graded by the patient. An overall opinion (poor, fair, good, very good) of the study drug was also made by both the patient and investigator at this time. In both groups, pethidine 75 mg IM PRN was prescribed for further analgesia. Patients were followed up at 24 hours.
Demographic data were compared using Student's t-test. The duration of analgesia (time from administration of study drug to time of request for further analgesia) was compared using both a Mann-Whitney test and a log-rank Mantel-Haentszel test on the Kaplan-Meier survival function. The decrease in pain VAS from initial values was compared between groups using the Mann-Whitney test. Categorical data were compared using X2 analysis. P values ::5 0.05 were considered significant.
RESULTS
Five patients did not request any further analgesia in the postoperative period and so five additional patients were recruited. Only one patient graded her initial pain severity as very severe. She was given IV morphine for analgesia and an additional patient was recruited into the study. There were 49 patients in the ketorolac group (41 severe pain, 8 moderate pain) and 51 in the pethidine group (41 severe pain, 10 moderate pain). Demographic data were similar between groups ( Table 1 ). The mean (SD) time from the end of anaesthesia to the administration of the study drug was similar in the ketorolac group, 24.6 (16.7) minutes, compared with the pethidine group 28.8, (20.9) minutes. Ten patients (4 ketorolac, 6 pethidine) did not request any further analgesia after the study medication. The duration of analgesia was similar in the ketorolac group compared with the pethidine group (Mann-Whitney: P=0.27, Mantel-Haentszel: P=O.l7, Figure 1 ). The pain VAS are shown in Figure 2 . Initial pain VAS were similar between groups. The decrease in pain VAS from initial values was greater for ketorolac than pethidine at 2 hours (P<O.Ol) and 3 hours (P<0.05). However, there were more patients in the pethidine group remaining under assessment at these times. There was no difference between groups in the 4-point verbal scale evaluation of pain and the overall subjective assessment of analgesia was similar between groups ( Table 2) . Ten patients in the pethidine group and two patients in the ketorolac group complained of nausea, vomiting or dizziness, although symptoms were present before the study for one patient in each group. This left one patient in the ketorolac group with dizziness, nausea and vomiting and nine patients in the pethidine group (6 nausea, 2 dizziness, 1 nausea, vomiting and dizziness) whose symptoms were thought to be related to the study drug. The number of patients reporting side-effects was significantly greater in the pethidine group (P<0.05).
There were no differences in the overall patient (Table  3 ) or investigator opinion of the two drugs. The duration of analgesia with ketorolac was not as long as that reported in previous studies. 4 Half the patients in the ketorolac group and a third of those in the pethidine group requested further analgesia within 90 minutes. This short durtion reflected the severity of pain and we may be criticised for giving insufficient analgesia initially. Nevertheless, in our practice, fentanyl 100 /kg may be satisfactory, as evidenced by the five patients who reqested no further postoperative analgesia and the ten patients who required only the single dose of study drug. Patients' attitudes to pain may vary considerably and individual titration of analgesia is preferable. It is disappointing that some patients rated the study drugs as providing poor analgesia. For those patients with early severe postoperative pain, it would have been preferable to give a drug intravenously to achieve rapid analgesia. Unfortunately, ketorolac is not licensed currently for intravenous administration in this country and it is not clear whether intravenous ketorolac would be as effective as intravenous opioids in this situation. Although the onset of ketorolac is said to be as rapid as that of opioids, the intramuscular route of administration leads to a considerable delay in onset.' Our findings are therefore more relevant to postoperative analgesia on the ward rather than during the time in recovery when the patient is still under the care of the anaesthetist.
This study used only a single dose of ketorolac but additional doses may be of benefit. Pethidine at the prescribed dose had a short duration of analgesia in this study but there are logistic problems and general reluctance on the post-natal ward to give an additional dose of pethidine shortly after the first. There are no such restrictions on the use of ketorolac, which may be given every two hours initially provided the total daily dose does not exceed 120 mg. 6 Ketorolac should be used in combination with opioids if indicated and single and multiple doses of ketorolac have a significant morphine-sparing effect. 7, 8 Ketorolac 10 mg has been compared with pethidine 50 mg and 100 mg for pain during labour. 9 Analgesia was inferior with ketorolac but maternal sedation and foetal depression were less. However, ketorolac is not recommended for use in labour 6 because there is placental transfer ID and concern about the effects of NSAIDs on the ductus arteriosus. Ketorolac is also not recommended currently for nursing mothers 6 because it is excreted in breast milk, although it has been calculated that the maximum foetal exposure via breast milk is only 0.4070 of maternal exposure. II All analgesics are excreted into breast milk and ketorolac compares favourably with other analgesics. 12 There have been other studies using NSAIDS for analgesia after caesarean section. A single dose of diclofenac 75 mg given before the end of general anaesthesia reduced papaveretum requirements compared with placebo. 13 (Papaveretum is no longer approved for use in pregnancy in Australia.) The mean papaveretum consumption in the diclofenac group was still approximately 36 mg in the first six hours but patients had lower pain VAS and sedation scores. Another study has shown a reduction in oxycodone Anaesthesia and Intensive Care, Vol. 21, No. 4, August, 1993 requirements after an infusion of either diclofenac 150 mg124 h or ketoprofen 200 mg124 h, compared with placebo, in patients after regional anaesthesia. 14 Intramuscular ketorolac has also been compared with epidural morphine for analgesia after caesarean section under epidural anaesthesia. 15 Preliminary results indicated that epidural morphine provided better analgesia but was associated with more side-effects. Other workers have investigated the combination of intramuscular diclofenac and epidural morphine after caesarean section under epidural anaesthesia. I. Diclofenac was thought to be particularly effective in relieving pain associated with uterine cramps, while epidural morphine provided analgesia for incisional wound pain.
In this study, there was a higher incidence of sideeffects in the pethidine group. Apart from improved patient comfort, the lack of side-effects with ketorolac may contribute to analgesia by increasing the acceptance of further doses. It was not possible to test this hypothesis in this study but it is known that the subjective request for further doses of opioids may be tempered by the wish to avoid opioid side-effects.
Although ketorolac 30 mg showed similar analgesic efficacy to pethidine 75 mg, ketorolac has a higher initial cost. A recent editorial has highlighted the necessity of determining whether new drugs are costeffective. 17 Ketorolac could reduce expenditure as a result of fewer side-effects and less administrative work compared with opioid drugs. Even if ketorolac is more expensive overall, it may in some situations provide more satisfactory analgesia than opioids and the question will then be whether the extra cost is worthwhile. Although there are estimates of the costs associated with administering opioid drugs, 18 we are not aware of published studies showing savings by using non-opioid drugs.
We conclude that ketorolac 30 mg and pethidine 75 mg have similar, short but variable efficacy after caesarean section. We consider the administration of either drug by the intramuscular route as generally unsatisfactory and unsuitable for the initial treatment of patients with severe pain when the intravenous route is available. Analgesic regimens should be individualised, and provided that effective analgesia is achieved immediately after surgery, we expect intramuscular ketorolac to be an alternative to intramuscular pethidine for further routine analgesia on the ward. Ketorolac should have fewer logistic problems associated with its administration because it is not subject to the strict regulations governing opioid drugs. Ketorolac also has a lower incidence of side-effects compared with pethidine but studies are still required to determine whether ketorolac is cost-effective.
